Skip to content
10-Q

Quarterly Report

Cantabio Pharmaceuticals Inc.

0001393905-18-000324

← back to feed
Filed
Nov 13, 2018 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2019 · Nov 9, 2018 81.95M sh
Operating Cash Flow Q2 2019 · Sep 30, 2018 −$352.9K
Operating Cash Flow Q2 2019 · Sep 30, 2017 −$283.08K
Cash And Equivalents Q2 2019 · Sep 30, 2018 $21.53K
Cash And Equivalents Q2 2019 · Mar 31, 2018 $109.43K
Cash And Equivalents Q2 2019 · Sep 30, 2017 $51.2K
Cash And Equivalents Q2 2019 · Mar 31, 2017 $32.28K
Stockholders Equity Q2 2019 · Sep 30, 2018 −$2.42M
Stockholders Equity Q2 2019 · Mar 31, 2018 −$1.87M
Current Liabilities Q2 2019 · Sep 30, 2018 $2.44M
Current Liabilities Q2 2019 · Mar 31, 2018 $1.98M
Total Liabilities Q2 2019 · Sep 30, 2018 $2.44M
Total Liabilities Q2 2019 · Mar 31, 2018 $1.98M
Current Assets Q2 2019 · Sep 30, 2018 $21.53K
Current Assets Q2 2019 · Mar 31, 2018 $109.43K
Total Assets Q2 2019 · Sep 30, 2018 $21.53K
Total Assets Q2 2019 · Mar 31, 2018 $109.43K
Sga Expense Q2 2019 · Sep 30, 2018 $155.13K
Sga Expense Q2 2019 · Sep 30, 2018 $279.78K
Sga Expense Q2 2019 · Sep 30, 2017 $177.44K
Sga Expense Q2 2019 · Sep 30, 2017 $368.17K
Rd Expense Q2 2019 · Sep 30, 2018 $79K
Rd Expense Q2 2019 · Sep 30, 2018 $190.22K
Rd Expense Q2 2019 · Sep 30, 2017 $98.9K
Rd Expense Q2 2019 · Sep 30, 2017 $196.1K
Net Income Q2 2019 · Sep 30, 2018 −$568.62K
Net Income Q2 2019 · Sep 30, 2018 −$1.04M
Net Income Q2 2019 · Sep 30, 2017 −$345.29K
Net Income Q2 2019 · Sep 30, 2017 −$697.69K